Omeros (NASDAQ:OMER) Announces Earnings Results

Omeros (NASDAQ:OMER – Get Free Report) released its quarterly earnings results on Monday. The biopharmaceutical company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.04, Zacks reports. The company had revenue of $35.93 million for the quarter, compared to analysts’ expectations of $37.28 million.

Here are the key takeaways from Omeros’ conference call:

  • YARTEMLEA sales continued to grow: Third-quarter gross sales rose 30% sequentially to $41.8 million and net sales increased 26% to $35.9 million. Management said momentum continued into the fourth quarter.
  • Commercial adoption and reimbursement access expanded: 109 accounts had ordered YARTEMLEA by quarter-end, up from 73 in June, and 80% of the top 40 U.S. transplant centers had approved it through their P&T committees. The company highlighted the new Medicare inpatient payment and outpatient reimbursement status as potential adoption advantages.
  • Omeros reported $13.3 million in operating cash flow for a second consecutive quarter and ended September with $95.3 million in cash and investments. GAAP results were a $57.4 million net loss, largely reflecting a $62 million non-cash mark-to-market loss; adjusted net income was $4.7 million.
  • European regulators issued a negative opinion on the narsoplimab marketing application for TA-TMA, and Omeros plans to stop accepting new patients into its European compassionate-use program. The company said it is pursuing approvals in other countries and reimbursed named-patient access programs.
  • The company plans to broaden YARTEMLEA development, with studies in hyperinflammatory ARDS and prevention of pediatric TA-TMA expected to start around year-end or early 2027. Separately, an animal-study delay pushed the planned start of the OMS527 cocaine-use-disorder trial to early 2027.

Omeros Stock Performance

Shares of OMER opened at $16.68 on Tuesday. Omeros has a fifty-two week low of $6.70 and a fifty-two week high of $21.24. The company has a market capitalization of $1.21 billion, a PE ratio of 6.59 and a beta of 2.96. The stock has a fifty day moving average of $18.22 and a two-hundred day moving average of $13.76.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on OMER shares. HC Wainwright restated a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Weiss Ratings raised shares of Omeros from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $22.00 price target on shares of Omeros in a research note on Wednesday, October 14th. Three research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.33.

Get Our Latest Stock Report on Omeros

Omeros News Roundup

Here’s some of the latest news about OMER:

  • Positive Sentiment: YARTEMLEA, Omeros’ treatment for transplant-associated thrombotic microangiopathy, generated $41.8 million in gross revenue in the quarter. The company is also working to expand education and outpatient use. Omeros third-quarter results
  • Positive Sentiment: Adjusted EPS was $0.06, ahead of analyst estimates. The improvement from a loss per share a year earlier offered a positive earnings signal. Zacks earnings report
  • Negative Sentiment: Revenue was $35.9 million, below the roughly $37.3 million expected by analysts, and reports highlighted a wider third-quarter loss. Those results likely outweighed the adjusted EPS beat and contributed to the negative reaction. MarketWatch report on the quarterly loss

Insiders Place Their Bets

In other news, CAO David Borges sold 10,000 shares of the firm’s stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $20.95, for a total transaction of $209,500.00. Following the sale, the chief accounting officer owned 5,000 shares in the company, valued at $104,750. This trade represents a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Cable sold 15,000 shares of Omeros stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $18.45, for a total value of $276,750.00. Following the completion of the sale, the director directly owned 35,067 shares of the company’s stock, valued at approximately $646,986.15. This represents a 29.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 100,906 shares of company stock worth $1,904,955 over the last ninety days. Company insiders own 10.50% of the company’s stock.

Omeros Company Profile

(Get Free Report)

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

Read More

Earnings History for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.